Overview

A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)

Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of ipecopam in the treatment of refractory/relapsed AIHA.
Phase:
NA
Details
Lead Sponsor:
Bing Han
Treatments:
iptacopan